Connect with us

News

MIMOSA™ by TaraCares exits beta, as start-up gears up for expansion

The platform will allow women to integrate their health data with intelligence from academic research and clinical excellence

Published

on

Jyoti Sharma, founder and CEO of TaraCares

MIMOSA™, a first-of-its-kind virtual precision health platform developed by TaraCares Global, has exited its beta phase, as the start-up prepares for launch in 11 international markets. 

MIMOSA aims to reimagine how female individuals of all ages, ethnicities and genders enter their unique menopause journey. 

Empowered with menopause health literacy individualised to the user’s flavour of the menopause transition and accompanying life circumstances, the platform will provide women with a longitudinal Menopause Health Graph™ and Menopause Health Risk Profile that integrates their health data with intelligence from academic research and clinical excellence.

A B2B HealthTech SaaS platform, MIMOSA  is currently available through employers. It has received glowing feedback from clinicians and individual users during the private launch that witnessed a user engagement rate of 84.38 per cent in 11 countries, including the four UK nations.

MIMOSAby TaraCares aims to educate and empower women throughout all the stages of the menopause

Dr/Prof. Vikram Sinai Talaulikar, a reproductive specialist at UCLH who has worked closely with TaraCares as a clinical advisor during the design and development of MIMOSA™ said: “The platform is easy to use, lovely images and colours, simple non-technical language so anyone can use it.

Dr Vikram Talaulikar, MD, FRCOG, PhD

“Out of comparable apps I have seen, MIMOSA™ stands out as comprehensive, inclusive, and easy-to-use,” Vikram, a certified menopause specialist by the British Menopause Society (BMS) and honorary associate professor at UCL, also added. 

A user involved in the Innovate UK funded research study led by TaraCares said: “The ‘trace your health’ feature is so easy to use. It has certainly helped me understand the symptoms I could be experiencing while staying focussed on my self-care and nutritional needs. Journaling my thoughts felt so reassuring and calming.”

Business impact

TaraCares is currently in discussions with several public and private organisations including FTSE100 companies in the UK for trial pilots of MIMOSA™

Last week, its founder and CEO, Jyoti Sharma, who has Indian origins and still reads Sanskrit, the ancient classical language of India in her spare time, announced the value-set that guides the decisions at TaraCares, adding “Be KRiiYa = Be Kind, Be Resilient, Be Intentional, Be Inspirational, Be You, Be Accountable.”

The company has been successful in signing established menopause corporate advisors and consultants as strategic alliances for their initial market penetration strategy, including Kirsty Dixon and Sally Duffin who have been appointed as strategic collaborators and members of the care team.

Describing herself as a postmenopausal woman with 12 years perimenopause experience under her belt, Dixon says her personal journey is her driving force to raise awareness and educate individuals and employers to ensure people receive research-based information and have access to the support they need to thrive. 

Kirsty Dixon, strategic collaborator and member of the care team at TaraCares Global

Following on from her work at the University of York, where she changed the culture around menopause through awareness raising and setting up support initiatives, she set up Pause for Thought Consultancy in 2022, to help employers to do the same.

“I love everything about TaraCares. MIMOSA is easy to use and everything is research focused so any information is up-to-date and above all correct,” Dixon said. 

“I class myself as a menopause educator so look forward to working with TaraCares. Also to be a critical friend and work alongside them to provide the best service for all who need menopause education and support.”

Duffin, another strategic collaborator, is a qualified registered nutritionist/nutritional therapist. She founded Nutrition in York to support support clients with digestive wellbeing, mental health, stress management, and hormonal issues. 

Sally Duffin, strategic collaborator and member of the care team at TaraCares Global

After a short break from clinical work to write her book Natural Nutrition for Perimenopause – What to Eat to Feel Good and Stay Sane, she returned to private nutrition practice to focus on menopause support. 

Duffin is a firm believer in the power of small steps that build healthy habits, understands the challenges clients face when trying to eat well and this is what excites her to be part of the team at TaraCares.

“TaraCares is built on a strong ethical foundation and has such a clear vision of what menopause care can and should look like. It’s exciting to be part of the team,” she said.

“We aim to support the whole menopause experience and provide accessible knowledge that users need to make informed, holistic decisions about their menopause transition.”

With MIMOSA expected to launch this summer, Sharma has revealed that several companies her team has been speaking to are already using solutions from competitors in the menopause space that have failed to deliver on the evidence base and benefits of the business case, highlighting the need for change and innovation. 

The MIMOSA™ platform will be available for both Android and iOS. To find out more, email Jyoti Sharma at jsharma@taracares.co.uk.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.